Reference
1. Chu JJ, Devall AJ, Beeson LE, Hardy
P, Cheed V, Sun Y, et al. Mifepristone and misoprostol versus
misoprostol alone for the management of missed miscarriage (MifeMiso): a
randomised, double-blind, placebo-controlled trial. Lancet 2020 Sep
12;396(10253):770-8.10.1016/S0140-6736(20)31788-8
2. Kapp N, Eckersberger E, Lavelanet
A, Rodriguez MI. Medical abortion in the late first trimester: a
systematic review. Contraception 2019
Feb;99(2):77-86.10.1016/j.contraception.2018.11.002
3. Wake DT, Ilbawi N, Dunnenberger HM,
Hulick PJ. Pharmacogenomics: Prescribing Precisely. The Medical clinics
of North America 2019 Nov;103(6):977-90.10.1016/j.mcna.2019.07.002
4. Woodland C, Koren G, Ito S. From
bench to bedside: utilization of an in vitro model to predict potential
drug-drug interactions in the kidney: the digoxin-mifepristone example.
Journal of clinical pharmacology 2003 Jul;43(7):743-50
5. Haslam IS, Jones K, Coleman T,
Simmons NL. Induction of P-glycoprotein expression and function in human
intestinal epithelial cells (T84). Biochemical pharmacology 2008 Oct
1;76(7):850-61.10.1016/j.bcp.2008.07.020
6. Tan Y, Cao K, Ren G, Qin Z, Zhao D,
Li N, et al. Effects of the ABCB1 and ABCG2 polymorphisms on the
pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica;
the fate of foreign compounds in biological systems 2020
Feb;50(2):237-43.10.1080/00498254.2019.1610585
7. Sakaeda T, Nakamura T, Okumura K.
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and
pharmacodynamics of drugs. Pharmacogenomics 2003
Jul;4(4):397-410.10.1517/phgs.4.4.397.22747
8. Jang GR, Wrighton SA, Benet LZ.
Identification of CYP3A4 as the principal enzyme catalyzing mifepristone
(RU 486) oxidation in human liver microsomes. Biochemical pharmacology
1996 Sep 13;52(5):753-61.10.1016/0006-2952(96)00357-7
9. Hamadeh IS, Zhang Q, Steuerwald N,
Hamilton A, Druhan LJ, McSwain M, et al. Effect of CYP3A4, CYP3A5, and
ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse
Events in Adult Allogeneic Stem Cell Transplant Patients. Biology of
blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 2019
Apr;25(4):656-63.10.1016/j.bbmt.2018.12.766
10. Zhao GX, Zhang Z, Cai WK, Shen
ML, Wang P, He GH. Associations between CYP3A4, CYP3A5 and SCN1A
polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
Epilepsy research 2021 Jul;173:106615.10.1016/j.eplepsyres.2021.106615
11. Saiz-Rodriguez M, Almenara S,
Navares-Gomez M, Ochoa D, Roman M, Zubiaur P, et al. Effect of the Most
Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic
Parameters of 10 CYP3A Substrates. Biomedicines 2020 Apr
22;8(4).10.3390/biomedicines8040094
12. Dong ZL, Li H, Chen QX, Hu Y, Wu
SJ, Tang LY, et al. Effect of CYP3A4*1G on the fentanyl consumption for
intravenous patient-controlled analgesia after total abdominal
hysterectomy in Chinese Han population. Journal of clinical pharmacy and
therapeutics 2012 Apr;37(2):153-6.10.1111/j.1365-2710.2011.01268.x
13. Su Q, Liu Q, Liu J, Fu L, Liu T,
Liang J, et al. Study on the associations between liver damage and
antituberculosis drug rifampicin and relative metabolic enzyme gene
polymorphisms. Bioengineered 2021
Dec;12(2):11700-8.10.1080/21655979.2021.2003930
14. Wu WN, McKown LA, Moyer MD,
Johannsen TB, Takacs AR. In vitro metabolism of mifepristone (RU-486) in
rat, monkey and human hepatic S9 fractions: identification of three new
mifepristone metabolites. Xenobiotica; the fate of foreign compounds in
biological systems 1999 Nov;29(11):1089-100.10.1080/004982599237976
15. Heikinheimo O, Kontula K,
Croxatto H, Spitz I, Luukkainen T, Lahteenmaki P. Plasma concentrations
and receptor binding of RU 486 and its metabolites in humans. Journal of
steroid biochemistry 1987 Feb;26(2):279-84.10.1016/0022-4731(87)90083-5
16. Tang C, Bi HC, Zhong GP, Chen X,
Huang ZY, Huang M. Simultaneous determination of mifepristone and
monodemethyl-mifepristone in human plasma by liquid
chromatography-tandem mass spectrometry method using levonorgestrel as
an internal standard: application to a pharmacokinetic study. Biomedical
chromatography : BMC 2009 Jan;23(1):71-80.10.1002/bmc.1086
17. Costescu D, Guilbert E, Bernardin
J, Black A, Dunn S, Fitzsimmons B, et al. Medical Abortion. Journal of
obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et
gynecologie du Canada : JOGC 2016
Apr;38(4):366-89.10.1016/j.jogc.2016.01.002
18. Creinin MD, Schreiber CA,
Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and
misoprostol administered simultaneously versus 24 hours apart for
abortion: a randomized controlled trial. Obstetrics and gynecology 2007
Apr;109(4):885-94.10.1097/01.AOG.0000258298.35143.d2
19. Wang N, Zhao H, Han W, He B,
Zhang S, Wang J. Association of the G2014G genotype in estrogen receptor
1 gene with failure of the mifepristone-induced termination of early
pregnancy. The Tohoku journal of experimental medicine 2010
Jan;220(1):77-82.10.1620/tjem.220.77
20. Schwab M, Eichelbaum M, Fromm MF.
Genetic polymorphisms of the human MDR1 drug transporter. Annual review
of pharmacology and toxicology
2003;43:285-307.10.1146/annurev.pharmtox.43.100901.140233
21. Wang D, Sadee W. Searching for
polymorphisms that affect gene expression and mRNA processing: example
ABCB1 (MDR1). The AAPS journal 2006 Aug
18;8(3):E515-20.10.1208/aapsj080361
22. Wang D, Johnson AD, Papp AC,
Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1)
variant 3435C>T affects mRNA stability. Pharmacogenetics
and genomics 2005 Oct;15(10):693-704
23. Geers LM, Pozhidaev IV, Ivanova
SA, Freidin MB, Schmidt AF, Cohen D, et al. Association between 8
P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic
drug-induced hyperprolactinaemia. British journal of clinical
pharmacology 2020 Sep;86(9):1827-35.10.1111/bcp.14288
24. Gusella M, Pasini F, Caruso D,
Barile C, Modena Y, Fraccon AP, et al. Clinical outcomes of oral
metronomic vinorelbine in advanced non-small cell lung cancer:
correlations with pharmacokinetics and MDR1 polymorphisms. Cancer
chemotherapy and pharmacology 2019
Mar;83(3):493-500.10.1007/s00280-018-3751-0
25. Parvin MN, Aziz MA, Rabbi SNI,
Al-Mamun MMA, Hanif M, Islam MS, et al. Assessment of the Link of ABCB1
and NR3C1 gene polymorphisms with the prednisolone resistance in
pediatric nephrotic syndrome patients of Bangladesh: A genotype and
haplotype approach. Journal of advanced research 2021
Nov;33:141-51.10.1016/j.jare.2021.02.001
26. Canaparo R, Finnstrom N, Serpe L,
Nordmark A, Muntoni E, Eandi M, et al. Expression of CYP3A isoforms and
P-glycoprotein in human stomach, jejunum and ileum. Clinical and
experimental pharmacology & physiology 2007
Nov;34(11):1138-44.10.1111/j.1440-1681.2007.04691.x
27. Krishna DR, Klotz U. Extrahepatic
metabolism of drugs in humans. Clinical pharmacokinetics 1994
Feb;26(2):144-60.10.2165/00003088-199426020-00007
28. Sumantran VN, Mishra P, Bera R,
Sudhakar N. Microarray Analysis of Differentially-Expressed Genes
Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and
Melanoma. Pharmaceutics 2016 Feb 17;8(1).10.3390/pharmaceutics8010004
29. Zhou Q, Yu X, Shu C, Cai Y, Gong
W, Wang X, et al. Analysis of CYP3A4 genetic polymorphisms in Han
Chinese. Journal of human genetics 2011
Jun;56(6):415-22.10.1038/jhg.2011.30
30. Chen B, Zhang XD, Wen J, Zhang B,
Chen D, Wang S, et al. Effects of 26 Recombinant CYP3A4 Variants on
Brexpiprazole Metabolism. Chemical research in toxicology 2020 Jan
21;33(1):172-80.10.1021/acs.chemrestox.9b00186
31. Liu J, Chen Z, Chen H, Hou Y, Lu
W, He J, et al. Genetic Polymorphisms Contribute to the Individual
Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in
Chinese GIST Patients. International journal of molecular sciences 2017
Mar 13;18(3).10.3390/ijms18030603
32. Park JW, Kim KA, Kim JM, Park IH,
Park JY. Influence of FMO3 and CYP3A4 Polymorphisms on the
Pharmacokinetics of Teneligliptin in Humans. Frontiers in pharmacology
2021;12:736317.10.3389/fphar.2021.736317
33. Han JM, Yee J, Chung JE, Lee KE,
Park K, Gwak HS. Effects of cytochrome P450 oxidoreductase genotypes on
the pharmacokinetics of amlodipine in healthy Korean subjects. Molecular
genetics & genomic medicine 2020 May;8(5):e1201.10.1002/mgg3.1201
34. Huang Y, Wen G, Lu Y, Wen J, Ji
Y, Xing X, et al. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the
antihypertensive efficacy of amlodipine in patients with hypertension
following renal transplantation. International journal of clinical
pharmacology and therapeutics 2017 Feb;55(2):109-18.10.5414/CP202559
35. Leminen R, Ranta S, von Hertzen
H, Oehler J, Heikinheimo O. Pharmacokinetics of 10 mg of mifepristone.
Contraception 2003 Dec;68(6):427-9.10.1016/s0010-7824(03)00181-1